Differential expression of long non-coding RNA SOX2OT in gastric adenocarcinoma

Abstract

BACKGROUND:

Gastric cancer (GC) is the third leading cause of cancer-related death in the world. Dysfunction of long noncoding RNAs (lncRNAs) in cancers, especially those with role in pluripotency, are approved by increasing evidence.

OBJECTIVE:

SOX2 overlapping transcript (SOX2OT) lncRNA, is aberrantly expressed in different cancers; however its role in gastric cancer is still controversial.

MATERIALS AND METHODS:

In this study, the expression of SOX2OT was evaluated in 33 matched pair tumor and non-tumor gastric samples and AGS and MKN45 gastric and NTERA2 embryonic carcinoma cell lines by real time PCR.

RESULTS:

Our finding revealed a significant decrease in the expression of SOX2OT in gastric tumor samples compared to their matched non-tumor samples ( $P=$ 0.05) and also a lower expression in high grade compared to low grade of gastric malignancy. As we expected SOX2OT expression showed higher expression in NT2 compared to AGS and MKN45 cell lines.

CONCLUSION:

Simultaneous expression of SOX2 and SOX2OT was reported in some cancers. Regarding to the decreased expression of SOX2OT in the present study in concurrent with downregulation of SOX2 in our previous study, it seems that SOX2OT plays a tumor suppressor role in GC and may be useful biomarker for diagnosis of GC.

Keywords

Long Non Coding RNA SOX2OT Gastric Cancer SOX2

1. Introduction

Long noncoding RNAs (lncRNAs), by more than 200 nt in length, play a crucial role in the transcriptional and post-transcriptional regulation of many genes in various processes (cell cycle, pluripotency, development, etc.). According to the reference human genome annotation for the ENCODE project (GENCODE release 23), it is estimated that our genome caries near to 16,000 genes that encode more than 28,000 well defined lncRNA transcripts [1]. Recently growing body of studies demonstrating the role of aberrantly expressed lncRNAs in cancer promotion and progression. Identification of lncRNAs with roles in cancer, especially those with tissue-specific expression pattern, eventually can leads to new prognostic biomarkers [2, 3, 4, 5].

There are similarities between early embryogenesis and tumourigenesis in different aspects such as cell invasive behaviors, gene expression and protein profile [6]. It has been showed that dysfunction of key pluripotency genes like SOX2 contributes in tumor initiation and progression [4]. SOX2 is settled down in the intronic region of a large lncRNA called SOX2 overlapping transcript (SOX2OT) and its transcription is regulated by SOX2OT in the same orientation. Therefore, it seems SOX2OT involves in pluripotency as well [5, 7, 8]. Aberrant expression of SOX2 and SOX2OT has been reported in some cancers [5, 9, 10]. Although, there is a controversy for SOX2 and SOX2OT expression in GC [3].

According to the Globocan 2012 database, GC is the third leading cause of cancer-related death worldwide. In Iran, Golestan in south of the Caspian Sea and Ardabil provinces have represented the highest incidence of GC [11, 12]. In our previous study, we reported a decreased expression of some key regulators of pluripotency including SOX2 gene in gastric cancer (GC) [5, 13].

Considering the impact of SOX2OT on SOX2 regulation, and contribution of pluripotency factors in tumorigenesis, the aim of the present study was to evaluate the expression pattern of SOX2OT and its correlation with SOX2 expression in gastric adenocarcinoma.

2. Materials and methods

2.1 Patients and clinical samples

Gastric adenocarcinoma and their matched non-tumor tissue samples were obtained from Iran National Tumor Bank (33 matched pairs) which is funded by the Cancer Institute of Tehran University, for Cancer Research. The experimental procedures were approved by the ethical boards of Tehran and Zanjan University of Medical Sciences (TUMS & ZUMS, A-12-861-1).

Table 1
Clinico-pathological characteristics of the patients with GC. A total of 33 pairs of gastric adenocarcinoma and their matched non-tumor tissue samples, were acquired. The stage of tumors was determined by TNM system according American Joint Committee on Cancer (AJCC). The system is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of distant metastasis (M)

Sample characteristics
	Number	Percentage
Gender
Female	9	27.27%
Male	24	72.73%
Year (age)
$>$ 55	27	81.82%
$<$ 55	6	18.18%
Differentiation
Grade I	11	33.33%
Grade II	10	30.31%
Grade III	12	36.36%
Lymph node
N0	12	36.37%
N1	14	42.42%
N2	5	15.15%
N3	2	6.06%
Invasion depth
T1	1	3.03%
T2	4	12.12%
T3	28	84.85%
Distance metastasis
M0	17	51.52%
M1	5	15.15%
Unknown	11	33.33%

2.2 Cell lines and cell culture

The human GC cell lines; AGS and MKN45 (Pasteur Institute of Iran) and embryonic carcinoma cell line NTERA2 (NT2; provided as a gift by Dr. Peter Andrews, Sheffield University) were cultured in appropriate media (DMEM or RPMI, Gibco) supplemented with penicillin/streptomycin (100 U/ml and 100 $\mu$ g/ml, respectively) and 10% FBS, at 37 ${}^{\circ}$ C in a humidified atmosphere of 5% CO ${}_{2}$ .

2.3 RNA extraction, cDNA synthesis and real-time PCR

TRIzol solution (Invitrogen) was used for total RNA extraction from both tissue samples and cell lines according to the manufacturer’s instruction. After performing DNase treatment (TAKARA), cDNA synthesis (TAKARA) was carried out and followed by quantitative real time PCR using SYBR Premix Ex Taq II (TAKARA) and Step One Plus instrument (Applied Biosystems). The primers of SOX2OT were designed on the last exon to detect all variants of SOX2OT (Table 2). The PCR efficiency value was obtained using LinRegPCR (12.x) method (AMC, http://LinRegPCR.nl). According to the evaluation of different endogenous genes (B2M, TBP, HPRT, B-ACT and GAPDH), B2M and GAPDH genes were chosen as the best reference genes in gastric tissue samples and used for normalization.

Table 2
The primer sequences used in the present study

Gene	Product length (bp)	Sequence
SOX2OT	189	F	5’-CCTGCGGTTGGAGTGTCAG-3’
		R	5’-GCTGTCATTCCTGGCTAAATC-3’
GAPDH	215	F	5’-GTGAACCATGAGAAGTATGACAAC-3’
		R	5’-CATGAGTCCTTCCACGATACC-3’
B2M	161	F	5’-CAGCAAGGACTGGTCTTTCTATCT-3’
		R	5’-CGGCATCTTCAAACCTCCAT-3’

F: Forward primer and R: Reverse primer.

2.4 Data analysis

Subsequent to the efficiency correction and normaliziation to internal controls, data analysis was conducted by GenEX software (MultiD) and Statistical Program for Social Sciences (SPSS) software version 20 (SPSS Inc.) according to Pffafl formula [14]. In brief, the expression level of SOX2OT in tumor and non tumor samples was normalized to that of the least expressed sample. Although, for comparative gene expression in different grades of gastric adenocarcinoma the fold change of gene expression in tumor samples was normalized related to non-tumor samples. A threshold value of 0.05 was considered to be statistically significant.

3. Results

3.1 Comparative SOX2OT gene expression in gastric samples

Despite of GC cell lines, the expression of SOX2OT was only detected in 64% of tumor and 54% of non-tumor gastric samples (data not shown). Comparing the expression of SOX2OT in tumor versus non tumor samples, a significant decrease was obtained in tumor samples ( $p=$ 0.05, Fig. 1).

Figure 1.

Comparative SOX2OT expression between tumor and non-tumor of gastric samples. Histograms show the median value of SOX2OT relative gene expression in tumor and non-tumor samples and circle is outlier. Note that the expression of SOX2OT is significantly down-regulated in tumor vs. non-tumor samples ( $p$ -value $=$ 0.05).

Furthermore SOX2OT showed a lower expression in high grade (III) compared to low grade (I and II) of gastric malignancy, although the statistically significance difference was borderline ( $p=$ 0.09). As it is obvious in Fig. 2, decreased expression of SOX2OT was obtained in all high-graded tumor samples compared to non-tumor samples (fold change $<$ 1).

Figure 2.

Comparative SOX2OT expression in different grades of gastric adenocarcinoma. A) Box plots show the median value of SOX2OT fold of gene expression (tumor vs. non-tumor samples) and circle is outlier.

3.2 Comparative SOX2OT gene expression in GC cell lines

The expression of SOX2OT compared between AGS and MKN45 human GC cell lines and NT2 embryonic carcinoma cell as a positive control for the expression of pluripotent factors. As we expected, SOX2OT expression was higher in NT2 compared to AGS and MKN45 cell lines (at least 20 times, $p<$ 0.01, Fig. 3). In concordance of tumor samples there was a low expression of SOX2OT in gastric cell lines.

Figure 3.

Comparision of SOX2OT expression in GC cell lines and NT2 embryonal carcinoma cells. Histograms represent value of means $\pm$ confidence interval 95% of relative gene expression from at least 3 independent experiments. Note that the expression of SOX2OT is significantly higher in NT2 embryonal carcinoma cells compared AGS and MKN45 gastric cell lines ( $p$ -value 0.01).

4. Discussion

Although overexpression of SOX2OT has been reported in some cancers such as esophageal squamous cell carcinoma [4, 9], breast [5] and lung cancer [10] and also in different cancer cell lines [7], there is still a controversy for the expression of SOX2OT in GC. While one report claimed the overexpression [15], the other report revealed a downregulation of SOX2OT expression in GC [16].

On the other hand, differential expression of SOX2 gene was reported in cancers [3]. while SOX2 plays an oncogenic role in esophagus [17], breast [18] and lung [19, 20], it showed SOX2 inhibits metastasis in GC [21]. Also currently, Sarkar et al have intensely clarified that SOX2 prevents tumorigenesis in gastric tissue through preventing Wnt/b-catenin signaling pathway and it has tumor suppressor activity in gastric tissue [22].

In our previous study, we reported a significant decreased of SOX2 expression beside other pluripotent factors in GC samples [23]. The same result was obtained for SOX2OT expression in the present study. On the other hand, it showed that the ectopic expression of SOX2OT in breast cancer leads to an almost 20-fold increase in SOX2 expression [5]. These results altogether indicate the concordance between SOX2OT and SOX2 gene expression.

SOXOT gene expression found to be correlated to poor prognosis in some cancers [24, 25]. In our study downregulation of SOX2OT was detected in all grades of malignancy, but, we didn’t detect any correlation between SOX2OT gene expression and lymph node metastasis (N), invasion depth (T) and distance of metastasis (M). The larger sample size may be needed to determine prognostic value of SOX2OT expression in GC.

Differential expression of SOX2T variants in tissue-specific manner and also origin of cancer might be able to explain the mentioned arguments about SOX2 and SOX2OT expression in different cancers [7]. Although, evaluating the expression of SOX2OT in gastric cancer stem cells (CSC) can be more valuable.

It showed that SOX2OT displays a highly expression in embryonic stem cells [7]. So we detected a high level of SOX2OT expression in accompany to SOX2 (data not shown) in NT2 rather than GC cell lines, AGS and MKN45.

5. Conclusion

Altogether, regarding to the regulatory role of SOX2OT in SOX2 expression there was a simultaneous decreased expression of SOX2OT and SOX2 in GC samples and cell lines. Therefore, it seems the same as SOX2, SOX2OT has tumor suppressor activity in GC as well and it may be useful biomarker for GC diagnosis.

Footnotes

Acknowledgments

This work was supported by a research grant from Cancer Gene Therapy Research Center (CGRC) and Student Research Committee, in Zanjan University of Medical Sciences (ZUMS). The sample of this study was provided by Iran National Tumor Bank (which is funded by the Cancer Institute of Tehran University, for Cancer Research). We are grateful to Dr. Forouzandeh Fereidooni, the previous head of the Iran Tumor Bank, Dr. Fatemeh Kamali and Dr. Amirnader Emami Razavi for supplying clinical samples and providing patient’s clinico-pathological information.

Conflict of interest

There is no conflict of interest between the authors.

References

Dykes

I.M.

and Emanueli

, Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA, Genomics Proteomics Bioinformatics 15 (2017), 177–186.

Bartonicek

Maag

J.L.

and Dinger

M.E.

, Long noncoding RNAs in cancer: mechanisms of action and technological advancements, Mol Cancer 15 (2016), 43.

Carrasco-Garcia

Santos

J.C.

Garcia

Brianti

Garcia-Puga

Pedrazzoli

, Jr. Matheu

and Ribeiro

M.L.

, Paradoxical role of SOX2 in gastric cancer, Am J Cancer Res 6 (2016), 701–13.

Shafiee

Aleyasin

S.A.

Vasei

Semnani

S.S.

and Mowla

S.J.

, Down-Regulatory Effects of miR-211 on Long Non-Coding RNA SOX2OT and SOX2 Genes in Esophageal Squamous Cell Carcinoma, Cell J 17 (2016), 593–600.

Khalili

Sadeghizadeh

Ghorbanian

Malekzadeh

Vasei

and Mowla

S.J.

, Down-regulation of miR-302b, an ESC-specific microRNA, in Gastric Adenocarcinoma, Cell J 13 (2012), 251–8.

Zhang

Wang

Yang

and Qin

, The relationship between early embryo development and tumourigenesis, J Cell Mol Med 14 (2010), 2697–701.

Saghaeian Jazi

Samaei

N.M.

Ghanei

Shadmehr

M.B.

and Mowla

S.J.

, Identification of new SOX2OT transcript variants highly expressed in human cancer cell lines and down regulated in stem cell differentiation, Mol Biol Rep 43 (2016), 65–72.

Amaral

P.P.

Neyt

Wilkins

S.J.

Askarian-Amiri

M.E.

Sunkin

S.M.

Perkins

A.C.

and Mattick

J.S.

, Complex architecture and regulated expression of the Sox2ot locus during vertebrate development, RNA 15 (2009), 2013–27.

Shahryari

Rafiee

M.R.

Fouani

Oliae

N.A.

Samaei

N.M.

Shafiee

Semnani

Vasei

and Mowla

S.J.

, Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma, Stem Cells 32 (2014), 126–34.

10.

Hussenet

Dali

Exinger

Monga

Jost

Dembele

Martinet

Thibault

Huelsken

Brambilla

and du Manoir

, SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas, PLoS One 5 (2010), e8960.

11.

Ferlay

Soerjomataram

Dikshit

Eser

Mathers

Rebelo

Parkin

D.M.

Forman

and Bray

, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer 136 (2015), E359–86.

12.

McLean

M.H.

and El-Omar

E.M.

, Genetics of gastric cancer, Nat Rev Gastroenterol Hepatol 11 (2014), 664–74.

13.

Arnold

Sarkar

Yram

M.A.

Polo

J.M.

Bronson

Sengupta

Seandel

Geijsen

and Hochedlinger

, Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice, Cell Stem Cell 9 (2011), 317–29.

14.

Pfaffl

, Relative quantification. In Real-time PCR, Edited by Dorak MT.New York: Taylor and Francis Group 63 (2006), 63–82.

15.

Zhang

Yang

Lian

and Xu

, LncRNA Sox2ot overexpression serves as a poor prognostic biomarker in gastric cancer, Am J Transl Res 8 (2016), 5035–5043.

16.

Zou

J.H.

C.Y.

Bao

and Zheng

G.Q.

, High expression of long noncoding RNA Sox2ot is associated with the aggressive progression and poor outcome of gastric cancer, Eur Rev Med Pharmacol Sci 20 (2016), 4482–4486.

17.

Boumahdi

Driessens

Lapouge

Rorive

Nassar

Le Mercier

Delatte

Caauwe

Lenglez

Nkusi

Brohee

Salmon

Dubois

del Marmol

Fuks

Beck

and Blanpain

, SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma, Nature 511 (2014), 246–50.

18.

Leis

Eguiara

Lopez-Arribillaga

Alberdi

M.J.

Hernandez-Garcia

Elorriaga

Pandiella

Rezola

and Martin

A.G.

, Sox2 expression in breast tumours and activation in breast cancer stem cells, Oncogene 31 (2012), 1354–65.

19.

Chou

Y.T.

Lee

C.C.

Hsiao

S.H.

Lin

S.E.

Lin

S.C.

Chung

C.H.

Chung

C.H.

Kao

Y.R.

Wang

Y.H.

Chen

C.T.

Wei

Y.H.

and Wu

C.W.

, The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer, Stem Cells 31 (2013), 2607–19.

20.

Hussenet

and du Manoir

, SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis, Cell Cycle 9 (2010), 1480–6.

21.

Chen

Huang

Zhu

Chen

Huang

Zhang

Chen

and Zhou

, SOX2 inhibits metastasis in gastric cancer, J Cancer Res Clin Oncol 142 (2016), 1221–30.

22.

Sarkar

Huebner

A.J.

Sulahian

Anselmo

Flattery

Desai

Sebastian

Yram

M.A.

Arnold

Rivera

Mostoslavsky

Bronson

Bass

A.J.

Sadreyev

Shivdasani

R.A.

and Hochedlinger

, Sox2 Suppresses Gastric Tumorigenesis in Mice, Cell Rep 16 (2016), 1929–41.

23.

Khalili

Vasei

Khalili

Alimoghaddam

Sadeghizadeh

and Mowla

S.J.

, Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma, J Gastrointest Cancer 46 (2015), 251–8.

24.

Shi

X.M.

and Teng

, Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis, Int J Clin Exp Pathol 8 (2015), 4008–14.

25.

Song

Yao

Liu

and Wang

, The prognostic value of long noncoding RNA Sox2ot expression in various cancers: A systematic review and meta-analysis, Clin Chim Acta 484 (2018), 52–59.

Differential expression of long non-coding RNA SOX2OT in gastric adenocarcinoma

Abstract

BACKGROUND:

OBJECTIVE:

MATERIALS AND METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Materials and methods

2.1 Patients and clinical samples

2.3 RNA extraction, cDNA synthesis and real-time PCR

Table 2 The primer sequences used in the present study

3. Results

3.1 Comparative SOX2OT gene expression in gastric samples

5. Conclusion

Footnotes

Acknowledgments

Conflict of interest

References

Table 2
The primer sequences used in the present study